Kura Oncology posts corporate presentation on KOMZIFTI launch and ziftomenib development strategy

Kura Oncology

Kura Oncology

KURA

0.00
  • Kura Oncology outlined plans to expand commercial uptake of KOMZIFTI (ziftomenib), following USD 5.8 million net product revenue in 1Q 2026, first full quarter of launch.
  • Cash, cash equivalents, short-term investments totaled USD 580.8 million as of March 31, 2026.
  • Funding runway expected to cover ziftomenib AML program through topline results from first pivotal Phase 3 KOMET-017 frontline trial, anticipated in 2028.
  • Strategy centers on moving ziftomenib into frontline AML via combinations such as 7+3 or venetoclax/azacitidine, targeting up to 50% of AML patients and a roughly USD 7 billion U.S. total addressable market.
  • Pipeline update highlighted darlifarnib combination studies in solid tumors, including cabozantinib in renal cell carcinoma and adagrasib in KRAS-driven cancers.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Kura Oncology Inc. published the original content used to generate this news brief on May 12, 2026, and is solely responsible for the information contained therein.

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.